The effect of histone deacetylase inhibition on BRCA1 expression: A potential novel mechanism for enhancing platinum sensitivity in breast and ovarian cancer

被引：0
|
作者：
Weberpals, Johanne I.
O'Brien, Anna
Garbuio, Kyla
Clark-Knowles, Katherine
Dimitroulakos, Jim
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B174
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
    Johanne I Weberpals
    Anna M O'Brien
    Nima Niknejad
    Kyla D Garbuio
    Katherine V Clark-Knowles
    Jim Dimitroulakos
    Cancer Cell International, 11
  • [2] The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
    Weberpals, Johanne I.
    O'Brien, Anna M.
    Niknejad, Nima
    Garbuio, Kyla D.
    Clark-Knowles, Katherine V.
    Dimitroulakos, Jim
    CANCER CELL INTERNATIONAL, 2011, 11
  • [3] Class Ⅰ histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
    Baoyuan Zhang
    Junfang Lyu
    Eun Ju Yang
    Yifan Liu
    Changjie Wu
    Lakhansing Pardeshi
    Kaeling Tan
    Qiang Chen
    Xiaoling Xu
    Chu-Xia Deng
    Joong Sup Shim
    Acta Pharmaceutica Sinica B, 2020, 10 (04) : 615 - 627
  • [4] Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
    Zhang, Baoyuan
    Lyu, Junfang
    Yang, Eun Ju
    Liu, Yifan
    Wu, Changjie
    Pardeshi, Lakhansing
    Tan, Kaeling
    Chen, Qiang
    Xu, Xiaoling
    Deng, Chu-Xia
    Shim, Joong Sup
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (04) : 615 - 627
  • [5] Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer
    Rhiem, K.
    Wappenschmidt, B.
    Bosse, K.
    Koeppler, H.
    Tutt, A. N.
    Schmutzler, R. K.
    CLINICAL ONCOLOGY, 2009, 21 (06) : 448 - 450
  • [6] BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
    Stefansson, Olafur A.
    Villanueva, Alberto
    Vidal, August
    Marti, Lola
    Esteller, Manel
    EPIGENETICS, 2012, 7 (11) : 1225 - 1229
  • [7] BRCA1 in breast and ovarian cancer predisposition
    Billack, B
    Monteiro, ANA
    CANCER LETTERS, 2005, 227 (01) : 1 - 7
  • [8] Inherited BRCA1 epimutation as a novel cause of breast and ovarian cancer
    Evans, D. G. R.
    van Veen, E. M.
    Byers, H. J.
    Wallace, A. J.
    Ellingford, J. M.
    Beaman, G.
    Santoyo-Lopez, J.
    Aitman, T. J.
    Eccles, D. M.
    Lalloo, F. I.
    Smith, M. J.
    Newman, W. G.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 419 - 420
  • [9] The evaluation of BRCA1 and ERCC1 expression as predictors of platinum response in ovarian cancer
    Weberpals, J. I.
    Clark-Knowles, K.
    O'Brien, A.
    Antoniouk, O.
    Garbuio, K.
    Dimitroulakos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report
    Salgado, Josefa
    Santisteban, Marta
    Gutierrez, Cristina
    Gil, Carmen
    Robles, Maitane
    Viedma, Adriana
    Patino-Garcia, Ana
    ONCOLOGY LETTERS, 2013, 6 (03) : 725 - 727
12345